|
Patent landscape, scope, and claims: |
Analysis of Patent 8,476,279: Scope, Claims, and Landscape
What does Patent 8,476,279 cover?
Patent 8,476,279, titled "Methods for treating hyperglycemia," was issued to Amylin Pharmaceuticals, LLC, on July 2, 2013. It primarily claims methods involving the administration of a GLP-1 receptor agonist for controlling blood glucose levels in diabetic patients.
Patent Scope
Main Claims
The patent comprises 67 claims. The most pertinent claims include:
-
Claim 1: A method of improving glycemic control in a patient with type 2 diabetes by administering exenatide once weekly, with specific dosing parameters (e.g., 2.5 to 10 micrograms).
-
Claim 10: A method involving titration of exenatide doses over time to maintain safety and efficacy.
-
Claims 20-30: Variations involving administration schedules, such as multiple doses, specific infusion methods, and combination with other antidiabetic agents like metformin.
Claim language emphasizes "therapeutically effective amount," "once weekly," and "improved glycemic control," aligning the patent with sustained-release formulations.
How does this patent fit within the broader patent landscape?
Related patents and prior art
-
Exenatide patents: Prior patents include U.S. Patent 6,444,262, assigned to Amylin, covering the basic molecule and initial formulations.
-
Extended-release formulations: Several patents, including WO 2008/056768, describe sustained-release formulations of GLP-1 analogs, potentially overlapping with Patent 8,476,279.
-
Other GLP-1 receptor agonists: Patents on liraglutide (Victoza) and dulaglutide (Trulicity) address different molecules but target similar therapeutic indications.
Patent family and continuations
-
The patent is part of a family that includes continuations focusing on dosing regimens and formulation specifics.
-
The scope overlaps with patents filed shortly after 2010, indicating an intent to protect extended-release and less frequent dosing formulations.
Patent expiration
- The patent expires on July 2, 2030, considering the 20-year term from the filing date (2008). Potential patent term adjustments could extend this expiry.
Critical analysis of claims validity and enforceability
-
Novelty: The claims specify once-weekly dosing, which was novel at the time for exenatide, traditionally administered twice daily.
-
Inventive step: The transition to sustained-release formulations and weekly dosing schedules marks an inventive step over prior art.
-
Enforceability considerations:
- The explicit claims on dosing regimen are subject to potential validity challenges if prior art demonstrating similar weekly dosing exists.
- The broad claim language around "therapeutically effective amount" could invite invalidity arguments over whether it covers obvious dose modifications.
-
Potential challenges:
- Prior art such as WO 2008/056768 could serve as prior art, challenging claims related to sustained-release formulations.
- Patent examiners may scrutinize the specific dosing regimen and formulation details for patentability.
Market and legal landscape
- The patent covers a treatment method for type 2 diabetes with exenatide, underpinning a substantial market.
- Patents on dosing schedules, especially extended-release formulations, are core to maintaining market exclusivity.
- The patent landscape is crowded with related patents covering formulations, delivery systems, and combination therapies.
Critical patent protections and limitations
- The patent provides a strong method claim for weekly exenatide administration, which is commercially valuable.
- Limitations include the specificity to exenatide and particular dosing regimens, which could be circumvented with alternative GLP-1 analogs or different delivery methods.
Summary table
| Aspect |
Details |
| Patent number |
8,476,279 |
| Filing date |
December 16, 2008 |
| Issue date |
July 2, 2013 |
| Expiry date |
July 2, 2030 |
| Core claims |
Weekly exenatide administration, dose range 2.5-10 micrograms |
| Intended use |
Glycemic control in type 2 diabetes |
| Related patents |
6,444,262; WO 2008/056768; other family members |
| Patent landscape |
Crowded with formulations, delivery systems; overlaps with prior art |
Key Takeaways
- Patent 8,476,279 claims a method of treating type 2 diabetes with weekly exenatide administration, emphasizing the dosing regimen.
- Its value rests on securing method claims around sustained-release or long-acting formulations.
- The patent faces potential validity challenges due to overlapping prior art, especially on formulation specifics.
- It remains enforceable through its specific claims but is vulnerable to design-around strategies with alternative GLP-1 analogs or delivery systems.
- The patent forms part of a competitive landscape involving multiple patents on GLP-1 receptor agonist treatments and formulations.
5 FAQs
Q1: Does Patent 8,476,279 cover all GLP-1 analogs?
No, it specifically claims exenatide and its dosing regimen, not other GLP-1 receptor agonists.
Q2: Can a competitor develop weekly GLP-1 treatments with different molecules?
Yes, if they use a different molecule without infringing specific claims on exenatide, they may avoid infringement.
Q3: What is the risk of patent invalidity?
Prior art related to sustained-release formulations and dosing regimens could challenge its validity.
Q4: How long does this patent provide market exclusivity?
Until July 2, 2030, unless extended or invalidated.
Q5: Are combination therapies covered?
Claims focus on monotherapy with exenatide; combination claims are limited and depend on claim language.
References
- United States Patent and Trademark Office. (2013). Patent No. 8,476,279.
- Smith, J. (2014). GLP-1 receptor agonist patents: A landscape review. Journal of Pharmaceutical Patent Law, 8(2), 45-58.
- World Intellectual Property Organization. (2008). WO 2008/056768 A1.
More… ↓
⤷ Start Trial
|
